La construction des mondes sociaux par la pratique de l'auto-publication: retour sur l'expérience de quelques blogueurs : JOURNALISTES ET CITOYENS: QUI PARLETREDAN, Olivier.Communication et langages. 2010, Num 165, issn 0336-1500, 73-86, 122, 124 [16 p.]Article

Le « journalisme citoyen » en ligne : Un public réifié ? : Paroles publiques: Communiquer dans la cité = Online citizen joumalism : a reified public? : Public Talks: Communicating in the CityTREDAN, Olivier.Hermès (Paris.1988). 2007, Num 47, pp 115-122, issn 0767-9513, 8 p.Article

Analyse rétrospective de la prise en charge des patientes du Centre Léon Bérard de plus de 70 ans présentant un cancer du sein localiséTREDAN, Olivier.2004, 121 p.Thesis

Trends in cancer-targeted antibody―drug conjugatesBIDARD, François-Clément; TREDAN, Olivier.Targeted oncology. 2014, Vol 9, Num 1, pp 1-8, issn 1776-2596, 8 p.Article

Journalisme et web : quels outils de formation?LE CAM, Florence; TREDAN, Olivier.MédiaMorphoses (Bry-sur-Marne). 2008, Num 24, pp 105-112, issn 1626-1429, 8 p.Article

Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissuesPATEL, Krupa J; TREDAN, Olivier; TANNOCK, Ian F et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 1, pp 127-138, issn 0344-5704, 12 p.Article

Les anticorps conjugués en oncologie: du concept au trastuzumab emtansine (T-DM1) = Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)GONCALVES, Anthony; TREDAN, Olivier; VILLANUEVA, Christian et al.Bulletin du cancer. 2012, Vol 99, Num 12, pp 1183-1191, issn 0007-4551, 9 p.Article

L'hypoxie tumorale peut-elle devenir un avantage pour la chimiothérapie ? = Can tumor hypoxia be turned into a chemotherapeutic advantage?TREDAN, Olivier; GRANTAB, Rama; DUMONTET, Charles et al.Bulletin du cancer. 2008, Vol 95, Num 5, pp 528-534, issn 0007-4551, 7 p.Article

Drug resistance and the solid tumor microenvironmentTREDAN, Olivier; GALMARINI, Carlos M; PATEL, Krupa et al.Journal of the National Cancer Institute. 2007, Vol 99, Num 19, pp 1441-1454, issn 0027-8874, 14 p.Article

The Hypoxia-Activated ProDrug AQ4N Penetrates Deeply in Tumor Tissues and Complements the Limited Distribution of MitoxantroneTREDAN, Olivier; GARBENS, Alaina B; LALANI, Alshad S et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 3, pp 940-947, issn 0008-5472, 8 p.Article

I-10 Q147 TUMEURS DU COL UTÉRIN, TUMEUR DU CORPS UTÉRIN = Cervix cancer and corpus cancer of the uterus O. Tredan, I. Ray-CoquardTREDAN, Olivier; RAY-COQUARD, Isabelle; ARNAUD, Antoine et al.La Revue du praticien (Paris). 2011, Vol 61, Num 10, pp 1435-1442, issn 0035-2640, 8 p.Article

Patients with metastatic breast cancer leading to CD4⁺ T cell lymphopaenia have poor outcomeTREDAN, Olivier; MANUEL, Manuarii; BLAY, Jean-Yves et al.European journal of cancer (1990). 2013, Vol 49, Num 7, pp 1673-1682, issn 0959-8049, 10 p.Article

Hormonorésistance des cancers du sein et inhibiteurs de mTOR = Antihormonal therapy in breast cancer and mTOR inhibitorsHEUDEL, Pierre-Etienne; TREDAN, Olivier; RAY-COQUARD, Isabelle et al.Bulletin du cancer. 2011, Vol 98, Num 12, pp 1431-1437, issn 0007-4551, 7 p.Article

CD4 lymphopenia to identify end-of-life metastatic cancer patientsPERON, Julien; CROPET, Claire; LABIDI GALY, Inthidar et al.European journal of cancer (1990). 2013, Vol 49, Num 5, pp 1080-1089, issn 0959-8049, 10 p.Article

Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group studyTREDAN, Olivier; TREILLEUX, Isabelle; LAVAU-DENES, Sandrine et al.Targeted oncology. 2013, Vol 8, Num 4, pp 243-251, issn 1776-2596, 9 p.Article

Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trialLE TOURNEAU, Christophe; KAMAL, Maud; POULIQUEN, Anne-Lise et al.Targeted oncology. 2012, Vol 7, Num 4, pp 253-265, issn 1776-2596, 13 p.Article

Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and LymphomasRAY-COQUARD, Isabelle; CROPET, Claire; GUASTAILA, Jean-Paul et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 13, pp 5383-5391, issn 0008-5472, 9 p.Article

Expression of class III β-tubulin is predictive of patient outcome in patients with non : Small cell lung cancer receiving vinorelbine-based chemotherapySEVE, Pascal; ISAAC, Sylvie; TREDAN, Olivier et al.Clinical cancer research. 2005, Vol 11, Num 15, pp 5481-5486, issn 1078-0432, 6 p.Article

Activité physique et survie après cancer = Physical activity and cancer survivalROMIEU, Isabelle; TOUILLAUD, Marina; SENESSE, Pierre et al.Bulletin du cancer. 2012, Vol 99, Num 10, pp 979-994, issn 0007-4551, 16 p.Article

Traitements adjuvants dans le cancer du sein: impact du résultat du curage axillaire en cas de micrométastase ou de cellules tumorales isolées dans le ganglion sentinelle = Adjuvant treatments in breast cancer: interest of completion of axillary dissection in case of micrometastases or isolated tumor cells in sentinel lymph nodeSCHMITT, Caroline; BOUTEILLE, Catherine; FAURE, Christelle et al.Bulletin du cancer. 2012, Vol 99, Num 4, pp 463-469, issn 0007-4551, 7 p.Article

Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994―1998 and 2003―2006GALY, Guillaume; INTIDHAR LABIDI-GALY, Sana; FAVIER, Bertrand et al.Breast cancer research and treatment. 2011, Vol 128, Num 1, pp 187-195, issn 0167-6806, 9 p.Article

Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian CancerINTIDHAR LABIDI-GALY, Sana; SISIRAK, Vanja; TREDAN, Olivier et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 16, pp 5423-5434, issn 0008-5472, 12 p.Article

Body weight change in women receiving adjuvant chemotherapy for breast cancer: A French prospective studyTREDAN, Olivier; BAJARD, Agathe; PEROL, David et al.Clinical nutrition (Edinburgh). 2010, Vol 29, Num 2, pp 187-191, issn 0261-5614, 5 p.Article